Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm Group, a global biopharmaceutical company, and Aurigene Discovery Technologies, a drug discovery biotechnology company, have signed an exclusive worldwide licensing agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialize Debio 0617, a novel inhibitor of an undisclosed oncology pathway.
Subscribe to our email newsletter
Under the terms of the agreement, Debiopharm will pay Aurigene an upfront fee, as well as further payments according to predefined discovery, development and sales milestones.
Rolland-Yves Mauvernay, president and founder of Debiopharm Group, said: “We are very excited to continue our collaboration with Aurigene. Their business model offers a one stop solution for structure guided drug design, lead optimization and preclinical work.
“The Debio 0617 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumors and haematological malignancies.”